Real-world comparison of treatment patterns and effectiveness of albiglutide and liraglutide.
To compare medication adherence, discontinuation and glycemic control in patients receiving albiglutide versus liraglutide. Administrative claims data and glycated hemoglobin (HbA1c) results were analyzed from a sample of adult health plan members with Type 2 diabetes. Patients were matched 1:1 in the albiglutide (n = 2213) and liraglutide (n = 2213) overall cohorts and in 244 patients with HbA1c results from each treatment group. Mean HbA1c change from baseline was -1.0% for both groups. At 6 months, mean ± standard deviation adherence was 0.69 ± 0.29 versus 0.64 ± 0.29 (p < 0.001), and discontinuation was 33.2 versus 37.8% (p = 0.002) with albiglutide versus liraglutide, but these were not statistically or clinically different at 12 months. Similar treatment patterns and clinically meaningful reductions in HbA1c were observed for both treatments in this real-world comparison.